Fintech

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Globenewswire·April 2, 2026 at 11:30 AM

MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

Treasury Proposes Stablecoin AML Framework
PYMNTS
Citi AI Cuts Account Opening Times
PYMNTS
Regulators Target Bank, FinTech AML Compliance
PYMNTS
Authenticity is key in AI-saturated market
PYMNTS

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Treasury Proposes Stablecoin AML Framework

Citi AI Cuts Account Opening Times

Regulators Target Bank, FinTech AML Compliance

Authenticity is key in AI-saturated market